Opthalmology

#Cell therapy #Eye health #Opthalmology

Are cell therapies the answer to age-related eye diseases?

In March 2026, Lineage Cell Therapeutics launched a new cell therapy programme for the treatment of corneal endothelial disease. Diana Turner caught up with Brian Culley, CEO of Lineage Cell Therapeutics, to find out more.  DT: How do you hope your in-house AlloSCOPE platform can overcome the problems and  practical hurdles associated with other cell… Read More

#Exclusive Content

#Biotech #Laboratoires Théa #Opthalmology

Biotech partnership to advance retinal drug pipeline 

Biotechnology company Iolyx Therapeutics has entered a strategic development and commercialisation agreement with ophthalmic specialty company Laboratoires Théa to advance its retinal pipeline.  Under the license and development agreement, Iolyx has granted Théa exclusive worldwide development and commercialisation rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.   Iolyx will receive up to… Read More

#Business & Investment #News